Imagion Biosystems Ltd (AU:IBX) — Market Cap & Net Worth
Market Cap & Net Worth: Imagion Biosystems Ltd (IBX)
Imagion Biosystems Ltd (AU:IBX) has a market capitalization of $5.21 Million (AU$7.36 Million) as of June 17, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28490 globally and #1536 in its home market, demonstrating a -6.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Imagion Biosystems Ltd's stock price AU$0.02 by its total outstanding shares 490590239 (490.59 Million). Review Imagion Biosystems Ltd total liabilities to assess the company's total debt and financial obligations.
Imagion Biosystems Ltd Market Cap History: 2017 to 2026
Imagion Biosystems Ltd's market capitalization history from 2017 to 2026. Data shows change from $1.28 Billion to $5.21 Million (-48.01% CAGR).
Imagion Biosystems Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Imagion Biosystems Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
268.09x
Imagion Biosystems Ltd's market cap is 268.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.28 Billion | $20.10K | -$7.79 Million | 63677.94x | N/A |
| 2018 | $392.74 Million | $191.48K | -$8.35 Million | 2051.09x | N/A |
| 2019 | $327.30 Million | $410.85K | -$3.43 Million | 796.64x | N/A |
| 2020 | $2.01 Billion | $205.72K | -$5.36 Million | 9786.83x | N/A |
| 2021 | $1.06 Billion | $232.87K | -$6.02 Million | 4531.62x | N/A |
| 2022 | $333.24 Million | $473.43K | -$9.81 Million | 703.88x | N/A |
| 2023 | $123.23 Million | $1.08 Million | -$12.47 Million | 113.79x | N/A |
| 2024 | $7.98 Million | $2.67 Million | -$2.07 Million | 3.00x | N/A |
| 2025 | $8.68 Million | $32.37K | -$4.31 Million | 268.09x | N/A |
Competitor Companies of IBX by Market Capitalization
Companies near Imagion Biosystems Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to Imagion Biosystems Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Imagion Biosystems Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Imagion Biosystems Ltd's market cap moved from $1.28 Billion to $ 5.21 Million, with a yearly change of -48.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$5.21 Million | -40.00% |
| 2025 | AU$8.68 Million | +8.70% |
| 2024 | AU$7.98 Million | -93.52% |
| 2023 | AU$123.23 Million | -63.02% |
| 2022 | AU$333.24 Million | -68.42% |
| 2021 | AU$1.06 Billion | -47.59% |
| 2020 | AU$2.01 Billion | +515.12% |
| 2019 | AU$327.30 Million | -16.66% |
| 2018 | AU$392.74 Million | -69.32% |
| 2017 | AU$1.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Imagion Biosystems Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.21 Million USD |
| MoneyControl | $5.21 Million USD |
| MarketWatch | $5.21 Million USD |
| marketcap.company | $5.21 Million USD |
| Reuters | $5.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Imagion Biosystems Ltd
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing th… Read more